SQZ Biotechnologies (SQZ) Stock Price, News & Analysis

Company Overview

SQZ Biotechnologies is a clinical-stage biotechnology company focused on developing cell-based therapies for a range of diseases, including cancer and autoimmune disorders. The company’s proprietary Cell Squeeze® platform enables the delivery of therapeutic cargo directly into the cytosol of cells by mechanically creating transient pores in the cell membrane. This approach is designed to enhance antigen presentation in immune cells, offering a novel route for generating potent and targeted immunotherapies.

Building on its platform, SQZ Biotechnologies has established a pipeline of product candidates that leverage both autologous and allogeneic cells. Lead programs include cancer vaccine candidates that aim to program a patient’s own antigen-presenting cells to recognize and attack tumors, as well as regulatory T-cell therapies for autoimmune indications. The platform’s modularity allows for rapid prototyping of multiple therapeutic modalities, from protein delivery to gene editing applications, positioning SQZ to address unmet medical needs across therapeutic areas.

Founded in 2014 and headquartered in Cambridge, Massachusetts, SQZ Biotechnologies went public in 2021 and maintains research and development facilities in the greater Boston area. Since its inception, the company has partnered with academic institutions and biopharmaceutical leaders to validate the Cell Squeeze technology in preclinical and early clinical settings. In addition to its U.S. base, SQZ collaborates with international research centers to accelerate global development and expand its clinical footprint.

The company’s leadership team brings together scientific pioneers and seasoned industry executives. Co-founder and Chief Scientific Officer Armon Sharei has overseen platform development since SQZ’s origin, while a management team with prior experience at leading biotechnology and pharmaceutical firms drives clinical and commercial strategy. Guided by a board of directors with deep expertise in cell therapy and immunology, SQZ Biotechnologies aims to translate its novel delivery technology into first-in-class treatments for patients worldwide.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.03 to $0.04
• 52-Week Range: $0.25 to $3.56
• Volume: N/A
• Average Volume: 455,220 shs
• Market Capitalization: $825.75 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SQZ Stock Analysis - Frequently Asked Questions

How have SQZ shares performed this year?

SQZ Biotechnologies' stock was trading at $0.03 at the beginning of the year. Since then, SQZ stock has decreased by 6.7% and is now trading at $0.0280.

How were SQZ Biotechnologies' earnings last quarter?

SQZ Biotechnologies (NYSE:SQZ) posted its earnings results on Wednesday, November, 10th. The company reported ($8.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.60) by $2.40. The company had revenue of $4.76 million for the quarter, compared to analyst estimates of $11.64 million. SQZ Biotechnologies had a negative trailing twelve-month return on equity of 119.83% and a negative net margin of 369.96%.

When did SQZ Biotechnologies' stock split?

Shares of SQZ Biotechnologies reverse split on Friday, July 7th 2023.The 1-10 reverse split was announced on Friday, July 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did SQZ Biotechnologies IPO?

SQZ Biotechnologies (SQZ) raised $75 million in an initial public offering on Friday, October 30th 2020. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Securities and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of SQZ Biotechnologies?

Shares of SQZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SQZ Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SQZ Biotechnologies investors own include Minerva Neurosciences (NERV), Illumina (ILMN), NVIDIA (NVDA), Oramed Pharmaceuticals (ORMP), Absci (ABSI), Allogene Therapeutics (ALLO) and Beam Therapeutics (BEAM).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 7/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Transportation
• Current Symbol: NYSE:SQZ
• CIK: 1604477
• Web: www.sqzbiotech.com
• Phone: 617-758-8672
• Fax: N/A
• Employees: 1,620
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$79.46 million
• Net Margins: -369.96%
• Pretax Margin: -408.99%
• Return on Equity: -119.83%
• Return on Assets: -59.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.50
• Quick Ratio: 3.50

Sales & Book Value

• Annual Sales: $18.16 million
• Price / Sales: 0.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.94 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 29,491,000
• Free Float: 24,772,000
• Market Cap: $825.75 thousand
• Optionable: Not Optionable
• Beta: 2.34